Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report
2
조회
0
다운로드
16
인용
0
참고문헌
키워드
초록
Objectives: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. Materials and Methods: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. Results: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0±10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. Conclusion: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
Abstract
Objectives: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. Materials and Methods: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. Results: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0±10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. Conclusion: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
참고문헌 (28)
- Urade M, "Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan", J Oral Maxillofac Surg, 69, pp.e364~e371 (2011)
- Otto S, "Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study", J Craniomaxillofac Surg, 39, pp.272~277 (2011)
- Vescovi P, "Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study", Oral Oncol, 47, pp.191~194 (2011)
- Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases", J Oral Maxillofac Surg, 62, pp.527~534 (2004)
- Park HM, "The use of osteoporosis medications in Korea in 2008", J Bone Metab, 16, pp.87~93 (2009)
- Ko JM, "Guidelines for diagnosis and treatment of osteoporosis" (2008), Sehung Dublishing
- Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- 김영란, "경구용 비스포스포네이트 관련 악골괴사의 합병증로 발생한 상악동염; 증례보고", 대한구강악안면외과학회지, 35(1), pp.39~40 (2009), 대한구강악안면외과학회
- 김경욱, "비스포스포네이트 관련 악골괴사의 진단 및 치료에 대한 임상적 연구", 대한구강악안면외과학회지, 37(1), pp.54~61 (2011), 대한구강악안면외과학회
- Hyo-jeong Son, "Oral bisphosphonates induced osteonecrosis of the mandible : A case report", 대한구강악안면외과학회지, 35(2), pp.106~111 (2009), 대한구강악안면외과학회
- 한윤식, "비스포스포네이트 관련 악골괴사에 대한 후향적 연구", 대한구강악안면외과학회지, 37(6), pp.470~476 (2011), 대한구강악안면외과학회
- Hoff AO, "Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates", J Bone Miner Res, 23, pp.826~836 (2008)
- review: bisphosphonates and osteonecrosis of the jaws, "Ann Intern Med", 2006, 753~761
- Bamias A, "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors", J Clin Oncol, 23, pp.8580~8587 (2005)
- Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update", J Oral Maxillofac Surg, 67(5 Suppl), pp.2~12 (2009)
- Khosla S, "American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
- Rizzoli R, "Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis", Bone, 42, pp.841~847 (2008)
- Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia", J Oral Maxillofac Surg, 65, pp.415~423 (2007)
- Lo JC, "Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure", J Oral Maxillofac Surg, 68, pp.243~253 (2010)
- Yoneda T, "Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons", J Bone Miner Metab, 28, pp.365~383 (2010)
- Abu-Id MH, ""Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw", J Craniomaxillofac Surg, 36, pp.95~103 (2008)
- Kimmel DB, "Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates", J Dent Res, 86, pp.1022~1033 (2007)
- Khan SA, "Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis", J Bone Miner Res, 12, pp.1700~1707 (1997)
- "Ministry for Health, Welfare and Family Affairs, Korean National Health and Nutrition Examination Survey in 2005"[URL]
- Choi HJ, "Burden of osteoporosis in adults in Korea: a national health insurance database study", J Bone Miner Metab, 30, pp.54~58 (2012)
- 장선미, "골다공증 환자의 의료이용 양상", Endocrinology and Metabolism, 25(4), pp.326~339 (2010), 대한내분비학회
- Lee YK, "Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry", Osteoporos Int, 24, pp.707~711 (2013)
- 대한내분비학회, "비스포스포네이트와 관련한 악골(턱뼈) 괴사", Endocrinology and Metabolism, 24(4), pp.227~230 (2009), 대한내분비학회